Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity
Author:
Funder
California Walnut Commission
Novo Nordisk
National Institute of Diabetes and Digestive and Kidney Diseases
Beth Israel Deaconess Medical Center
Publisher
Elsevier BV
Subject
Critical Care and Intensive Care Medicine,Nutrition and Dietetics
Reference51 articles.
1. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?;Kokkinos;Metabolism,2019
2. The role of glicentin and oxyntomodulin in human metabolism: new evidence and new directions;Perakakis;J Clin Endocrinol Metab,2020
3. Pharmacotherapy of obesity: available medications and drugs under investigation;Pilitsi;Metab Clin Exp,2019
4. Pharmacotherapy of type 2 diabetes: an update;Upadhyay;Metab Clin Exp,2018
5. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis;Perakakis;Liver Int,2021
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond;Metabolism;2024-02
2. Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery;Metabolism;2023-11
3. Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals;Clinical Nutrition;2023-08
4. Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study;Diabetes, Obesity and Metabolism;2023-05-29
5. Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetes in a year–A cross-sectional and prospective analysis;Diabetes Research and Clinical Practice;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3